Eltrombopag may cause hepatotoxicity, especially if administered in combination with interferon and ribavirin in patients with chronic hepatitis C (may increase the risk of hepatic decompensation).
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
Patients who carry this polymorphism in F5 are associated with an increased risk of thromboembolism when treated with eltrombopag.
Patients who carry this polymorphism in SERPINC1 are associated with antithrombin III deficiency and an increased risk of thromboembolism when treated with eltrombopag.
| Deferasirox | The serum concentration of Eltrombopag can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Eltrombopag can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Eltrombopag can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Eltrombopag can be decreased when it is combined with Teriflunomide. |
| Irinotecan | The risk or severity of neutropenia can be increased when Eltrombopag is combined with Irinotecan. |
| Calcium acetate | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium acetate. |
| Calcium glucoheptonate | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium glucoheptonate. |
| Calcium chloride | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium chloride. |
| Calcium | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium. |
| Calcium carbonate | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium carbonate. |
| Calcium citrate | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium citrate. |
| Calcium gluconate | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium gluconate. |
| Calcium Phosphate | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium Phosphate. |
| Calcium lactate | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium lactate. |
| Calcium lactate gluconate | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium lactate gluconate. |
| Calcium pangamate | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium pangamate. |
| Calcium polycarbophil | The serum concentration of Eltrombopag can be decreased when it is combined with Calcium polycarbophil. |
| Deferiprone | The serum concentration of Deferiprone can be increased when it is combined with Eltrombopag. |
| Mifepristone | The serum concentration of Eltrombopag can be increased when it is combined with Mifepristone. |
| Sucralfate | Sucralfate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bentoquatam | Bentoquatam can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium sulfate | Magnesium sulfate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium | Aluminium can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium oxide | Magnesium oxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium salicylate | Magnesium salicylate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Kaolin | Kaolin can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc | Zinc can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc trihydroxide | Zinc trihydroxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc Substituted Heme C | Zinc Substituted Heme C can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum hydroxide | Aluminum hydroxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magaldrate | Magaldrate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Potassium alum | Potassium alum can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium hydroxide | Magnesium hydroxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Polaprezinc | Polaprezinc can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium trisilicate | Magnesium trisilicate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc oxide | Zinc oxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc sulfate | Zinc sulfate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium chloride | Magnesium chloride can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium carbonate | Magnesium carbonate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Talc | Talc can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum chloride | Aluminum chloride can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium citrate | Magnesium citrate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc citrate | Zinc citrate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc picolinate | Zinc picolinate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum sulfate | Aluminum sulfate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc gluconate | Zinc gluconate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bentonite | Bentonite can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium silicate | Magnesium silicate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium acetoacetate | Aluminium acetoacetate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hydrotalcite | Hydrotalcite can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium aspartate | Magnesium aspartate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium peroxide | Magnesium peroxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium glycinate | Aluminium glycinate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aloglutamol | Aloglutamol can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Montmorillonite | Montmorillonite can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium gluconate | Magnesium gluconate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium orotate | Magnesium orotate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetylcysteine zinc | Acetylcysteine zinc can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc ascorbate | Zinc ascorbate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc acetate | Zinc acetate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc glycinate | Zinc glycinate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium | Magnesium can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium levulinate | Magnesium levulinate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium lactate | Magnesium lactate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium phosphate | Aluminium phosphate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc chloride | Zinc chloride can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc sulfate, unspecified form | Zinc sulfate, unspecified form can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc cation | Zinc cation can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum oxide | Aluminum oxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nelfinavir | The metabolism of Eltrombopag can be increased when combined with Nelfinavir. |
| Desogestrel | The metabolism of Eltrombopag can be increased when combined with Desogestrel. |
| Zidovudine | The metabolism of Eltrombopag can be increased when combined with Zidovudine. |
| Lamotrigine | The metabolism of Eltrombopag can be increased when combined with Lamotrigine. |
| Efavirenz | The metabolism of Eltrombopag can be increased when combined with Efavirenz. |
| Tipranavir | The metabolism of Eltrombopag can be increased when combined with Tipranavir. |
| Ethinylestradiol | The metabolism of Eltrombopag can be increased when combined with Ethinylestradiol. |
| Testosterone propionate | The metabolism of Eltrombopag can be increased when combined with Testosterone propionate. |
| Rosuvastatin | The serum concentration of Rosuvastatin can be increased when it is combined with Eltrombopag. |
| Iron Dextran | Iron Dextran can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron | Iron can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prussian blue | Prussian blue can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron sucrose | Iron sucrose can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric pyrophosphate | Ferric pyrophosphate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric ammonium citrate | Ferric ammonium citrate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxsil | Ferumoxsil can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxides | Ferumoxides can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric sulfate | Ferric sulfate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous bisglycinate | Ferrous bisglycinate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gleptoferron | Gleptoferron can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric oxide | Ferric oxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perflubutane | Perflubutane can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous sulfate anhydrous | Ferrous sulfate anhydrous can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium feredetate | Sodium feredetate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric hydroxide | Ferric hydroxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric cation | Ferric cation can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous gluconate | Ferrous gluconate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous succinate | Ferrous succinate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous fumarate | Ferrous fumarate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetraferric tricitrate decahydrate | Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric oxyhydroxide | Ferric oxyhydroxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |